Genome response to tissue plasminogen activator in experimental ischemic stroke

BackgroundTissue plasminogen activator (tPA) is known to have functions beyond fibrinolysis in acute ischemic stroke, such as blood brain barrier disruption. To further delineate tPA functions in the blood, we examined the gene expression profiles induced by tPA in a rat model of ischemic stroke.ResultstPA differentially expressed 929 genes in the blood of rats (p ≤ 0.05, fold change ≥ |1.2|). Genes identified had functions related to modulation of immune cells. tPA gene expression was found to be dependent on the reperfusion status of cerebral vasculature. The majority of genes regulated by tPA were different from genes regulated by ischemic stroke.ConclusionstPA modulates gene expression in the blood of rats involving immune cells in a manner that is dependent on the status of vascular reperfusion. These non-fibrinolytic activities of tPA in the blood serve to better understand tPA-related complications.

[1]  B. Wong,et al.  Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy , 2009, The Pharmacogenomics Journal.

[2]  C. Molina,et al.  Recanalization and Reperfusion Therapies for Acute Ischemic Stroke , 2009, Cerebrovascular Diseases.

[3]  G. Boysen,et al.  Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. , 1999, Stroke.

[4]  Jeffrey F. Thompson,et al.  Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in Rat , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  K. Rouschop,et al.  Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury. , 2005, Journal of the American Society of Nephrology : JASN.

[6]  R. Bordet,et al.  Involvement of Thrombolysis in Recombinant Tissue Plasminogen Activator-Induced Cerebral Hemorrhages and Effect on Infarct Volume and Postischemic Endothelial Function , 2003, Stroke.

[7]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[8]  D. Lawrence,et al.  Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. , 2003, The Journal of clinical investigation.

[9]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[10]  N. Nighoghossian,et al.  Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  S. L. Mehta,et al.  Molecular targets in cerebral ischemia for developing novel therapeutics , 2007, Brain Research Reviews.

[12]  G. Albers,et al.  Symptomatic Intracerebral Hemorrhage following Thrombolytic Therapy for Acute Ischemic Stroke: A Review of the Risk Factors , 2007, Cerebrovascular Diseases.

[13]  P. Lapchak,et al.  Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)–Induced Hemorrhage After Thromboembolic Stroke , 2000, Stroke.

[14]  S. Papson,et al.  “Model” , 1981 .

[15]  K. Furie,et al.  Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke , 2006, Neurology.

[16]  M. Chopp,et al.  Atorvastatin Downregulates Tissue Plasminogen Activator-Aggravated Genes Mediating Coagulation and Vascular Permeability in Single Cerebral Endothelial Cells Captured by Laser Microdissection , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  M. Chopp,et al.  Synergistic Effect of an Endothelin Type A Receptor Antagonist, S-0139, With rtPA on the Neuroprotection After Embolic Stroke , 2008, Stroke.

[18]  M. Chopp,et al.  Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. , 1999, Stroke.

[19]  R. Tibshirani,et al.  Statistical Applications in Genetics and Molecular Biology Pre-validation and inference in microarrays , 2011 .

[20]  K. Hayashi,et al.  Tissue Plasminogen Activator Enhances the Hypoxia/reoxygenation-induced Impairment of the Blood–brain Barrier in a Primary Culture of Rat Brain Endothelial Cells , 2008, Cellular and Molecular Neurobiology.

[21]  J. Gregg,et al.  Gene Expression in Peripheral Blood Differs after Cardioembolic Compared with Large-Vessel Atherosclerotic Stroke: Biomarkers for the Etiology of Ischemic Stroke , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  M. Karjalainen‐Lindsberg,et al.  An emerging role of mast cells in cerebral ischemia and hemorrhage , 2009, Annals of medicine.

[23]  J. Gregg,et al.  Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. , 2006, Genomics.

[24]  A. Shah,et al.  Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. , 2005, American journal of physiology. Heart and circulatory physiology.

[25]  M. Karjalainen‐Lindsberg,et al.  Mast Cell Stabilization Reduces Hemorrhage Formation and Mortality After Administration of Thrombolytics in Experimental Ischemic Stroke , 2007, Circulation.

[26]  S. Warach,et al.  Thrombolytic Toxicity: Blood Brain Barrier Disruption in Human Ischemic Stroke , 2008, Cerebrovascular Diseases.

[27]  K. Rhodes,et al.  Extension of the Thrombolytic Time Window With Minocycline in Experimental Stroke , 2008, Stroke.

[28]  K. Arai,et al.  Lipoprotein receptor–mediated induction of matrix metalloproteinase by tissue plasminogen activator , 2003, Nature Medicine.

[29]  F R Sharp,et al.  Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: Blood genomic fingerprints of disease , 2001, Annals of neurology.

[30]  J. Montaner,et al.  Tissue plasminogen activator (t‐PA) promotes neutrophil degranulation and MMP‐9 release , 2008, Journal of leukocyte biology.

[31]  Joseph F. Clark,et al.  Gene Expression in Blood Changes Rapidly in Neutrophils and Monocytes after Ischemic Stroke in Humans: A Microarray Study , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  R. Bordet,et al.  Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia , 2009, British journal of pharmacology.

[33]  K. Furie,et al.  Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke , 2004, Stroke.

[34]  David F. Moore,et al.  Using Peripheral Blood Mononuclear Cells to Determine a Gene Expression Profile of Acute Ischemic Stroke: A Pilot Investigation , 2005, Circulation.

[35]  C. Ali,et al.  Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic , 2009, Trends in Neurosciences.

[36]  P. Weinstein,et al.  Reversible middle cerebral artery occlusion without craniectomy in rats. , 1989, Stroke.